MRUS Merus N.V.

Merus BV is a clinical stage immuno-oncology company. It is engaged in developing bispecific antibody therapeutics.

$22.69  +0.05 (0.20%)
As of 07/01/2022 10:09:09 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  The Netherlands
Country of incorporation:  The Netherlands
IPO date:  05/19/2016
Outstanding shares:  43,550,059
Average volume:  444,069
Market cap:   $962,891,804
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BZBY005

---

Valuation   (See tab for details)

---

PE ratio:   -13.05
PB ratio:   3.31
PS ratio:   18.37
Return on equity:   -25.40%
Net income %:   -144.16%